Printer Friendly

CYTOCARE BUYS RIGHTS TO PROSTATE CANCER ANTIBODIES

 CYTOCARE BUYS RIGHTS TO PROSTATE CANCER ANTIBODIES
 IRVINE, Calif., Dec. 20 /PRNewswire/ -- Cytocare Inc.


(NASDAQ: CYTI) announced the acquisition of world-wide exclusive rights for diagnostic, prognostic and therapeutic uses of certain hybridoma cell lines and their prostate monoclonal antibodies. The patented molecules were licensed from the Sloan-Kettering Institute for Cancer Research.
 These compounds, after further rigorous testing, might be developed for potential use as biopharmaceutical agents for prostate disease. Cytocare is developing a family of molecules for the diagnosis and treatment of benign prostatic hypertrophy and prostate cancer.
 Pharmaceutical projects inherently are high risk. In 1992, Cytocare intends to expand research and development in small molecule synthesis, human monoclonal antibodies and conjugation chemistry for prostate disease.
 Urology Marketing Efforts Expands
 Cytocare also announced that Medstone International Inc., its manufacturing subsidiary, added two new distributors for both U.S. and foreign markets: the Liebel-Flarsheim Co., a leading supplier of urological examining rooms, and Lithotech Inc., a supplier of lithotripsy hardware.
 -0- 12/20/91
 /CONTACT: Jeannine Cormane of Cytocare Inc., 714-587-0500, ext. 345/
 (CYTI) CO: Cytocare Inc. ST: California IN: MTC SU:


DM-CH -- LA010 -- 4394 12/20/91 12:55 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 20, 1991
Words:190
Previous Article:GLOBAL OCEAN CARRIERS ANNOUNCES COMPLETION OF RIGHTS OFFERING SALE OF 1,111,111 SHARES RAISED GROSS PROCEEDS OF $5,000,000
Next Article:1992 PORSCHE 968 LAUNCHED AT $39,850 SUGGESTED RETAIL PRICE
Topics:


Related Articles
CYTOGEN AND CYTORAD REPORT FAVORABLE RESULTS IN PROSTATE CANCER IMAGING
Progenics and Cytogen Develop Antibodies to Treat Prostate Cancer.
Millennium and BZL Biologics agree to develop antibodies against prostate cancer.
New Tools for Prostate Cancer Diagnostics.
DakoCytomation Signs Agreement on Novel Prostate Cancer Markers.
Protein Design Labs Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to Genentech, Inc.
BioWa, Inc., Licenses Anti-FGF8 Antibody from Kyowa Hakko Kogyo Co., Ltd.
BioWa, Inc., Licenses Anti-FGF8 Antibody from Kyowa Hakko Kogyo Co., Ltd.
Arius announces new findings in Trop-2 and CD59 CANCER antibody programs - CD59 antibody uses novel approach to "de-cloak" cancers -.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters